Experience with GnRH-Agonists in Ovarian Stimulation

Author(s):  
K. Diedrich ◽  
R. Schmutzler ◽  
Ch. Diedrich ◽  
H. van der Ven ◽  
S. Al-Hasani ◽  
...  
2021 ◽  
pp. 33-38
Author(s):  
A. G. Syrkasheva ◽  
D. M. Ermakova

This literature review focuses on the use of corifollitropin alfa for ovarian stimulation in assisted reproductive technology (ART) programmes in different groups of patients. Corifollitropin alfa is a gonadotropin drug with prolonged FSH activity. The main difference between corifollitropin alfa and other gonadotropins is the higher level of peak FSH, which leads to the recruitment of more follicles. Another feature is the inability to adjust the gonadotropin dose during the first days of ovarian stimulation. In contrast to traditional indications/contraindications for gonadotropins, the use of cortifollitropin is not recommended in combination with GnRH agonists or in patients with polycystic ovary syndrome.Evidence for the feasibility and efficacy of using corifollitropin alfa in patients with various ovarian response variants in ART programmes has been analysed. Most researchers agree that the use of corifollitropin alfa can be recommended for patients with a presumed poor or normal ovarian response. The use of corifollitropin alfa in patients with a presumed excessive response to ovarian timulation is possible when embryo transfer is not expected: in oocyte donation/oocyte vitrification cycles or in "freeze-all" cycles.A significant advantage of using corifollitropin alfa for oocyte donor patients is the single administration of the drug, which can be done in a medical facility, which reduces the risk of prescription non-compliance.The use of corifollitropin alfa in protocols with GnRH agonists requires further research: firstly, corifollitropin alfa has no LH component and secondly, there is no possibility of ovulation trigger replacement in this protocol if there is a high risk of early ovarian hyperstimulation syndrome.


Author(s):  
S. V. Zhukovskaya ◽  
L. F. Mozhejko

Different protocols of controlled ovarian stimulation have a significant influence on ovarian hyperstimulation syndrome (OHSS) patterns in women who undergo in vitro fertilization programs (IVF).The objective of this research was to evaluate the impact of different ovarian stimulation protocols on various clinical and laboratory parameters of OHSS, such as embryologic characteristics, hormonal changes, hemostasis, and IVF outcomes. The study was made on the basis of the MPUE “Center of Reproductive Medicine” (Minsk, Belarus) and included,in total, 718 women who underwent IVF for infertility treatment. 103 patients developed OHSS and were divided into two groups based on hormonal stimulation protocols: Group 1 included 60 women who were stimulated with gonadotrophin releasing hormone (GnRH) agonists protocol; Group 2 consisted of 43 women who were prescribed GnRH antagonists during ovarian stimulation.In Group 1 (ovarian stimulation protocol with GnRH agonists), we established significantly higher serum concentrations of estradiol and progesterone during IVF and more marked hemostatic shift towards hypercoagulation: statistically significant elevation of fibrinogen and D-dimes simultaneously with decrease in the primary anticoagulants (antithrombin III and protein С) functional activity. Also, Group 1 had a significantly higher incidence of the early form of OHSS and embryo transfer cancellation caused by a high risk of severe OHSS.OHSS that has developed after the GnRH agonists protocol of controlled ovarian stimulation is associated with higher risks of complications and lower chances of successful pregnancy, which is explained by hyperestrogenic state, elevated progesterone levels, marked hypercoagulation, and higher incidence of early OHSS, which leads to the necessity of embryo transfer cancellation.


Author(s):  
Hrishikesh D. Pai ◽  
Pritimala Bhalchandra Gangurde ◽  
Nandita P. Palshetkar ◽  
Rishma Dhillon Pai

1996 ◽  
Vol 11 (Supplement_5) ◽  
pp. 123-132
Author(s):  
Gary Hodgen

2014 ◽  
Vol 122 (03) ◽  
Author(s):  
V Seifert-Klauss ◽  
AC Ritzinger ◽  
B Lesoine ◽  
M Kiechle ◽  
M Schmidmayr ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document